A triplet of pioneers in fourth round of presentations at BLSS 2019

In this round of talks, attendees of BioStock Life Science Summit 2019 got to listen to three companies tackling a wide range of indications. Dicot’s drug development is centred on male sexual dysfunction; WntResearch, on the hand, focuses on preventing the spread of metastases from tumour cells; meanwhile, Idogen’s target is autoimmune disease: when the body’s immune system attacks itself. See the full-length presentations below!Göran Beijer, CEO of Dicot, kicked off the fourth round of company presentations at this year’s BioStock Life Science Summit by discussing solutions to male sexual dysfunction. The company is developing a drug with potential to treat both erectile dysfunction and premature ejaculation, Libiguin. The active substance stems from a Madagascar tree and will reinstate spontaneity into the patients sex life. The candidate is currently in preclinical development.

Then the focus shifted to cancer with WntResearch, presented by CEO Peter Morsing. The company is developing a new type of cancer treatment that works by inhibiting the ability of tumor cells to spread throughout the body and form metastases. Their main candidate, Foxy-5, has gone through successful preclinical and phase I trials in patients with colon, prostate or breast cancer. A phase II trial in colon cancer is underway and interim data are expected in 2020.

The third presentation of this round brought the discussion full circle back to autoimmune diseases and chronic inflammatory diseases with Idogen being presented by CEO Anders Karlsson. Idogen is a Swedish biotechnology company that develops tolerogenic cell therapies to prevent the patient’s immune system from attacking the body’s own cells or tissue in the case of autoimmune diseases or organ transplantations. The company’s most advanced candidate is IDO 8, designed to treat patients with severe haemophilia A who have developed resistance to standard treatment.

See the three company presentations below.